THE NOVEL NOMOGRAM OF GLEASON SUM UPGRADE: POSSIBLE APPLICATION FOR THE ELIGIBLE CRITERIA OF LOW DOSE RATE BRACHYTHERAPY ArticleBudäus L., Graefen M., Salomon G., Schlomm T., Steuber T., Haese A., Heinzer H., Huland H., Isbarn H., Chun F.K., Fisch M., Koellermann J., Sauter G., Lughezzani G., Sun M., Karakiewicz P.I.International Journal of Urology. Vol. 17. 2010. P.. 862-868
THE PROSTATE CANCER GENE 3 (PCA3) URINE TEST IN MEN WITH PREVIOUS NEGATIVE BIOPSIES: DOES FREE-TO-TOTAL PROSTATE-SPECIFIC ANTIGEN RATIO INFLUENCE THE PERFORMANCE OF THE PCA3 SCORE IN PREDICTING POSITIVE BIOPSIES? ArticlePloussard G., Bastien L., Abbou C.C., De La Taille A., Haese A., Huland H., Stenzl A., Feyerabend S., Van Poppel H., Marberger M., Remzi M., Tinzl M., Mulders P.F.A., Stillebroer A.B., Van Gils M.P.M.Q., Schalken J.A.BJU International. Vol. 106. 2010. P.. 1143-1147
DIFFERENCES IN BIOPSY FEATURES BETWEEN PROSTATE CANCERS LOCATED IN THE TRANSITION AND PERIPHERAL ZONE ArticleErbersdobler A., Graefen M., Jaekel T., Haese A., Huland H., Hammerer P.G., Augustin H.BJU International. Vol. 91. 2003. P.. 477-481
CYCLOOXYGENASE-2 PROMOTES ANGIOGENESIS IN PTA/T1 UROTHELIAL BLADDER CARCINOMA BUT DOES NOT PREDICT RECURRENCE ArticleToma M.I., Petri S., Huland H., Friedrich M.G.BJU International. Vol. 92. 2003. P.. 389-392
COMPARISON OF MULTITARGET FLUORESCENCE IN SITU HYBRIDIZATION IN URINE WITH OTHER NONINVASIVE TESTS FOR DETECTING BLADDER CANCER ArticleToma M.I., Hellstern A., Pantel K., Weisenberger D.J., Noldus J., Huland H., Friedrich M.G.BJU International. Vol. 92. 2003. P.. 911-914